In late September 2004, the cardiovascular risks identified in a placebo-controlled adenoma-
prevention trial that was terminated early precipitated the voluntary withdrawal from the …

BACKGROUND & AIMS:: Colorectal cancer is one of the leading causes of cancer death.
Most colorectal cancers are believed to develop from colorectal adenomas. We examined …

OBJECTIVES: Subjects in the Prevention of Colorectal Sporadic Adenomatous Polyps
(PreSAP) trial (PRESAP/NCT00141193/www. clinicaltrials. gov) were studied to determine …

Colorectal cancer (CRC) is among the most common human malignancies and remains a
leading cause of cancer-related morbidity and mortality. Colorectal carcinogenesis is a …

The limited success of current treatments for most advanced common malignancies
highlights the importance of cancer prevention. Clinical trials on cyclooxygenase (COX) …

CRC development is a multi-step process that spans 10 to 15 years, thereby providing an
opportunity for early detection and even prevention. The poor survival rate of advanced CRC …

Colorectal cancer is an excellent model for studying cancer prevention by means of
secondary (eg, polypectomy to remove a precursor adenoma) and primary …

Background & Aims: Our aim was to establish the incidence of symptomatic upper
gastrointestinal ulcers, ulcer perforation, ulcer obstruction, or bleeding episodes (PUBs) …

Approximately six years after the cyclooxygenase-2 (COX-2) inhibitors were approved for
use in the United States, the results of three randomized, placebo-controlled trials provide …

OBJECTIVE: To discuss the role of nonsteroidal antiinflammatory drugs (NSAIDs) in the
chemoprevention of colorectal cancer. DATA SOURCES: A MEDLINE search (1966–May …